510(k) device
OrthoGold 100
Tissue Regeneration Technologies, LLC · Extracorporeal Shock Wave Device For Treatment Of Diabetic Foot Ulcers (PZL, Class II) · First FDA decision Aug 28, 2020, newest Aug 28, 2020Chronic wounds and ulcersDiabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
4
Naming "OrthoGold 100"
MAUDE reports
1
Brand "OrthoGold 100", since 2015
PubMed studies
1
Mentioning "OrthoGold 100"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OrthoGold 100
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- OrthoGold 100510(k)
K200926 · Decided Aug 28, 2020 · 143 days after receipt
Device type: Extracorporeal Shock Wave Device For Treatment Of Diabetic Foot Ulcers (PZL) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Services Provided for the Diagnosis and Treatment of Diabetic Sensory Neuropathy with Loss of Protective Sensation (aka Diabetic Peripheral Neuropathy)National determinationOn the books70.2.1Updated Aug 17, 2023
- Treatment of Decubitus UlcersNational determinationOn the books270.4Updated Apr 20, 2020
- Extracorporeal Shock Wave Therapy (ESWT)Local determinationIn effectL38775Palmetto GBAUpdated Sep 6, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "OrthoGold 100", any status and sponsor, newest update first.
- NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After InjuryPivotal-lookingRecruiting
AUVAAcademic, hospital or other
NCT04474106 · 246 participants (planned) · Start Jul 2, 2020 · Primary completion Dec 31, 2026
Device: Shock waves; dummy head · For: Acute Traumatic Spinal Cord Injury
Sites: Innsbruck, Austria; Bad Häring, Austria; Feldkirch, Austria · 15 sites in all
Ludwig Boltzmann GesellschaftAcademic, hospital or other
NCT03147313 · 60 participants (planned) · Start Apr 18, 2017 · Primary completion Apr 2023
Device: MTS Medical UG Orthogold 100; Sham · For: Peripheral Nerve Injury
Sites: Vienna, Austria · 2 sites in all
Medical University of ViennaAcademic, hospital or other
NCT01695928 · 30 participants · Start Sep 2012 · Primary completion Dec 2013
Device: Extracorporeal shockwave therapy; ESWT placebo · For: Mesial Movement of Teeth; Miniscrew Stability
Sites: Vienna, Austria
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OrthoGold 100", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PZL
2 reports: 0 malfunction, 2 injury, 0 death
Newest reports for this brand
MW5107111 · Received Jan 31, 2022 · Event dated Jan 24, 2022
Device type: Massager, Therapeutic, Electric (ISA)
Device problem as coded: Patient-Device Incompatibility; Therapeutic or Diagnostic Output Failure
Patient problem as coded: Pain; Burning Sensation; Inadequate Pain Relief; Numbness
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "OrthoGold 100"[tiab]. The summary above synthesizes these.
- Efficacy of Unfocused Medium-Intensity Extracorporeal Shock Wave Therapy (MI-ESWT) for Plantar Fasciitis.
Fansa A, Talsania AJ, Kennedy JG, et al. · J Foot Ankle Surg · 2021
Other devices of this type
Also filed under product code PZL.
- OW100SSoftwave/Trt, LLC · 510(k) 2024
- DOLORCLAST Focused Shock WavesE.M.S Electro Medical Systems S.A · 510(k) 2025
- CS-Pro MEDCurative Sound Therapeutics · 510(k) 2025
- Storz Medical Duolith SD1 T-Top & Tower System with C-Actor Sepia HandpieceStorz Medical AG · 510(k) 2021
- OrthoGoldTissue Regeneration Technologies · 510(k) 2019
- dermaPACE SystemSanuwave, Inc. · De Novo 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.